M.D

American Shared Hospital Services Pays Tribute to Ernest A. Bates, M.D., Founder and Former Chairman and CEO

Retrieved on: 
Tuesday, March 26, 2024
MRI, Radiosurgery, UCSF, Jacobi Medical Center, ASHS, Executive, Trustee, SAN, Black, University, MD, Medical Center, Dentistry, University of California, Johns Hopkins University, AMS, M.D

Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.

Key Points: 
  • Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.
  • He expanded accessibility to centers throughout the U.S. and in South America, building a solid foundation for American Shared Hospital Services’ future success.
  • Known for his intellectual curiosity, generous philanthropy, and longstanding service and dedication to American Shared Hospital Services, Dr. Bates was widely known in the healthcare industry and forged long-term friendships throughout his lifetime.
  • He previously provided consulting services to the Company pursuant to a consulting agreement from December 2021 through March 2022 before rejoining the Board in March 2022.

Dr. Gary K. Michelson and Alya Michelson Receive 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Annual Gathering for Cure Awards

Retrieved on: 
Friday, March 22, 2024
Biotechnology, Health, Philanthropy, Oncology, Neurology, Mental Health, Health Technology, Research, Surgery, Foundation, Science, Brain mapping, Brain, Bowman-Biltmore Hotels, Innovation Park, Survival, ALS, Patient, Public policy, Immunology, Scientist, GFC, City, Neuroscience, Pioneer, Doctor of Philosophy, Mental health, Quality of life, Health policy, DSM-IV codes, Invention, Therapy, Intellectual property, Physician, M.D, State, Human

Inventor and philanthropist Dr. Gary K. Michelson and his wife Alya Michelson received the 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Gathering for Cure (GFC) Awards Gala at the Biltmore Hotel in Los Angeles.

Key Points: 
  • Inventor and philanthropist Dr. Gary K. Michelson and his wife Alya Michelson received the 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Gathering for Cure (GFC) Awards Gala at the Biltmore Hotel in Los Angeles.
  • The Humanitarian Award is given to individuals who have contributed significantly to survival and quality of life of patients across the Globe.
  • Previous recipients of the annual award include Dr. Anthony Fauci, Dr. Sanjay Gupta, and Ming Hsieh.
  • The World Brain Mapping Foundation focuses on helping wounded soldiers, brain and spine cancers, neurodegenerative disorders (Parkinson’s, Alzheimer’s, ALS, MS, etc.

Incredible Health Releases Fifth Annual State of Nursing Report, as Incredible Health's Marketplace Reaches One Million US Nurses and 1,500 US Hospitals

Retrieved on: 
Thursday, March 14, 2024
Employment, HR, Health, Trust, COVID-19, SAN, Patient, Hospital, Artificial intelligence, AI, Overalls, Generation Z, Nursing, Retirement, M.D, Family, Government

SAN FRANCISCO, March 14, 2024 /PRNewswire/ -- Incredible Health, the largest healthcare career marketplace, announced today the release of its highly anticipated State of US Nursing Report, now in its fifth year. This year's report marks a significant milestone for the platform, as it now boasts a staggering one million US nurses and has expanded its reach to support over 1,500 hospitals across the United States. The report, which includes the platform's proprietary data of one million US nurses and results from a survey of more than 3,300 nurses, sheds light on the critical challenges facing nurses in today's healthcare landscape, highlighting the ongoing staffing shortages as a major concern.

Key Points: 
  • "Incredible Health is proud to reach monumental milestones in pursuing our mission to help healthcare workers live better lives," said Iman Abuzeid, M.D, co-founder and CEO of Incredible Health.
  • The results of our State of US Nursing Report inspire action by health systems and government, just like our past reports."
  • Cardiac Care, Medical-Surgical, and Operating Room specialty nurses saw the highest spike in demand from health systems on the Incredible Health marketplace.
  • 21% of nurses have relocated to a different state for a role through the Incredible Health marketplace.

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Retrieved on: 
Monday, March 4, 2024
Phenotype, Breakfast, Informatics, EST, Booth, Exome, Common, Nursing care plan, Down syndrome, Genetics, American College, ACMG, Genetic testing, M.D, Automation, Medical genetics, Transcriptome, Research, Whole genome sequencing, Pharmaceutical industry

HOUSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Key Points: 
  • The presentations shed light on cutting-edge developments in genetic analysis, diagnostic interpretation, and clinical results, underscoring Baylor Genetics’ mission to translate scientific innovation into accessible clinical solutions that improve patient outcomes and advance precision diagnostics.
  • "These presentations reflect our ongoing commitment to advancing the field of genetics and empowering patients, providers, and partners with insights and innovations to transform healthcare and improve lives."
  • Customers and partners interested in attending the breakfast can request an invitation and register here or inquire onsite at the Baylor Genetics booth.
  • Learn more about ACMG’s Annual Clinical Genetics Meeting through the conference website and visit the Baylor Genetics’ website to explore the company’s genetic testing capabilities.

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024
M.D, SAN, Oppenheimer Holdings, Therapy, Event, Conference

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Key Points: 
  • SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
  • Please contact your Oppenheimer & Co. institutional salesperson to participate in the event.
  • Links to the replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at investor.oncternal.com, for at least 30 days after the event.

Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024

Retrieved on: 
Tuesday, January 23, 2024
Silicon, Whole genome sequencing, M.D, Patient, DSM-IV codes, Harvard University, Intensive care medicine, NICU, Baylor College of Medicine, Gene, WGS, Blog, Genetics, WES, Genetic testing, PICU, Conference, NIH, Sequence, Genome, Clinical trial, Bangladesh Technical Education Board, Hall, Diagnosis, UDN

Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).

Key Points: 
  • Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).
  • Baylor Genetics and partner Baylor College of Medicine have served as the sole sequencing core for UDN since its inception in 2014, providing WGS/WES testing, interpretation, validation and reporting for patients with rare genetic diseases.
  • The Harvard Gazette recently published one such story, noted in a Baylor Genetics blog on navigating the maze of undiagnosed diseases.
  • Learn more about PMWC through the conference website and visit the Baylor Genetics website to explore the company’s full spectrum of genetic testing capabilities.

MemorialCare Heart & Vascular Institute at Orange Coast Medical Center Earns 4 out of 5 Three-Star Ratings for Coronary Artery Bypass Surgery

Retrieved on: 
Monday, January 29, 2024
Mortality, Anesthesiology, Family, Participation, M.D, Patient, ACSD, Intubation, Hospital, Kidney failure, Health, Surgeon, Survival, Society, Stroke, CHSD, STS, CABG, Disease, Database, Benchmarking, Task force, Physician

FOUNTAIN VALLEY, Calif., Jan. 29, 2024 /PRNewswire/ -- MemorialCare Orange Coast Medical Center cardiac surgeons have earned distinguished three-star ratings from The Society of Thoracic Surgeons (STS) for its patient care and outcomes in isolated coronary artery bypass grafting (CABG) procedures.  The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score. The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.

Key Points: 
  • The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score.
  • The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.
  • The star rating is calculated using a combination of quality measures for specific procedures performed by an STS Adult Cardiac Surgery Database participant.
  • Some important measures include absence of morbidity and mortality, percentage of rapid extubation, and use of arterial conduits.

Vintage Philanthropy: Hollander Foundation Pours $20,000 into Prostate Cancer Research from Wine-Making Proceeds

Retrieved on: 
Tuesday, January 2, 2024
Immunotherapy, University, Research, Health, Prostate cancer, Wine, College, Cancer, Poverty, City University, M.D, NIH, DEPT, Pharmaceutical industry

GAINESVILLE, Fla., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Supported by non-profit wine making, The Hollander Foundation, committed to supporting prostate cancer research, awarded its annual gift to Eugene Shenderov, M.D. of Johns Hopkins University School of Medicine. Dr. Shenderov is an Assistant Professor with the Dept. of Genitourinary Oncology and Cancer Immunology and the Co-Director Prostate Cancer Multi-Disciplinary Clinic at Hopkins. Dr. Shenderov's lab focuses on the understanding of the mechanisms of the immune response to prostate cancer and the resistance to immunotherapy. This has led to advanced research in next generation therapies involving checkpoint inhibition and cancer immunotherapy.

Key Points: 
  • Supported by non-profit wine making, The Hollander Foundation, committed to supporting prostate cancer research, awarded its annual gift to Eugene Shenderov, M.D.
  • Dr. Shenderov's lab focuses on the understanding of the mechanisms of the immune response to prostate cancer and the resistance to immunotherapy.
  • GAINESVILLE, Fla., Jan. 2, 2024 /PRNewswire-PRWeb/ -- Supported by non-profit wine making, The Hollander Foundation , committed to supporting prostate cancer research, awarded its annual gift to Eugene Shenderov, M.D .
  • After he was diagnosed with prostate cancer at an incurable stage in 2010, Dr. Hollander, a highly-regarded clinician/teacher at the Gainesville VA Medical Center, affiliated with the University of Florida, then created his Foundation to fund prostate cancer research.

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Patient, Quality of life, Division, Death, Relapse, Pancytopenia, Cytokine release syndrome, Disease, LBL, Blood, EMD, SAN, Gene, Graft-versus-host disease, EMRA, CRC, ASH, CD38, Oncology, M.D, CRS, T-ALL, Fungal infection, Cell, Medicine, Phenotype, Pharmaceutical industry

“For a disease that disproportionately affects younger individuals, the need to find better treatments feels especially urgent,” said Armin Ghobadi, M.D, associate professor of medicine and clinical director of Center for Gene and Cellular Immunotherapy (CGCI) in the Division of Medical Oncology at the Washington University School of Medicine in St. Louis. “It’s encouraging to see positive momentum -- with favorable tolerability and efficacy data continuing to be reported as the study has expanded to include more patients with such difficult-to-treat blood cancers.”

Key Points: 
  • An investigational allogeneic CAR-T cell therapy, WU-CART-007 is being studied for the treatment of patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL).
  • In the latest update, an additional 13 patients were treated with WU-CART-007, which showed clinically acceptable safety profiles and preliminary evidence of anti-leukemic activity, demonstrating a notable clinical improvement.
  • Positive and consistent data from the WU-CART-007 Phase 1/2 trial collectively underscore its potential to address unmet medical needs for difficult-to-treat blood cancers as it advances to the next crucial phase of development.
  • In evaluable patients at DL≥ 2 (18/22), the Composite Complete Remission Rate (CRc) in patients was 67%.

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Retrieved on: 
Monday, December 4, 2023
Phase, Immune system, Infection, AstraZeneca, Executive Committee, Doctor of Philosophy, Novartis, Neoplasm, Celgene, M.D, Hematology, Patient, Bristol Myers Squibb, Sanofi, Bone marrow, Vaccine

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Key Points: 
  • Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
    PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy platform to fully and rapidly re-arm the immune system against tumors and infection, today announces the appointment of Dr. Abderrahim (Rahim) Fandi as Chief Medical Officer, effective immediately.
  • Dr Fandi brings more than 25 years of experience of oncology clinical development programs in the pharmaceutical and biotechnology industry.
  • Prior to this, Rahim held senior clinical research and development positions at Celgene, Novartis, Bristol Myers Squibb and AstraZeneca.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “Rahim’s extensive experience in clinical development to explore new immuno-oncology technologies will be an invaluable asset to Smart Immune.